Genome Therapeutics
Biotechnology Research • 
Cambridge, England, United Kingdom • 1-10 Employees
Company overview
| Headquarters | Lensfield Road, Yusuf Hamied, Dept. of Chemistry, Cambridge, England CB2 1EW, GB |
| Website | |
| NAICS | 541714 |
| Founded | 2022 |
| Employees | 1-10 |
Key Contact at Genome Therapeutics
Eeson Rajendra
Senior Director, Head Of Biology
About Genome Therapeutics
Founded in 2022, Genome Therapeutics (GTx) was formed to advance pioneering academic research from the laboratories of Professor Sir Shankar Balasubramanian at the University of Cambridge and Professor Samuel Aparicio at the University of British Colombia. GTx is developing novel therapies that target secondary DNA structures called G-quadruplexes (G4) that are overrepresented in cancer cells. This novel approach to cancer therapeutics is underpinned by 25 years’ of academic research, paving the way for GTx to develop first-in-class therapies that precisely target the underlying genetic drivers of cancer and avoid the indiscriminate toxicity profile of classical chemotherapy agents.
Genome Therapeutics revenue & valuation
| Annual revenue | $769,995 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,500,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Genome Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Genome Therapeutics has never raised funding before.
United States
Canada
South Africa
Frequently asked questions
4.8
40,000 users
